- Amplia Therapeutics (ATX) has ended the week in a trading halt as it plans for an upcoming capital raise
- So far, it is unknown how much the company is aiming to raise and where the funds will be spent
- Company shares will be paused until Tuesday, May 4, or when more information is released to the market
- On the market, Amplia shares last traded at 28.5 cents per share on April 29
Amplia Therapeutics (ATX) has entered into a trading halt ahead of an upcoming capital raise.
Currently, there is no information on how much the company is aiming to raise and where the funds will be spent.
Under the halt, company shares will be paused until Tuesday, May 4, or when more information is released to the market.
Amplia is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
Earlier this week, Amplia received further data from its collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research in Sydney, for its FAK inhibitors.
The research tested the company’s AMP945 candidate in a range of in-vitro and in-vivo experimental systems developed by Professor Timpson.
Amplia says the drug impacted several key markers of disease, including the level of fibrosis and collagen maturity in the tumour environment within a mouse model of pancreatic cancer.
Due to this, the company is planning a phase two clinical trial in pancreatic cancer patients.
On the market, Amplia shares last traded at 28.5 cents per share on April 29.